SG3 Management’s Agilon Health AGL Stock Holding History

SG3 Management’s Portfolio AGL Stock Details AGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,200	Closed	-$761K	–	404
2022 Q1	$761K	Buy	+1,200	New	+$618K	0.02%	520

Other funds holding AGL

CDR

Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCP

Durable Capital Partners Bethesda, Maryland $9.71B AUM 26.27% 1-Year Est. Return

SG3 Management's AGL Position: Q2 2022 in Review

SG3 Management sold out of Agilon Health (AGL) in Q2 2022, closing a stake of 3,000 shares — an estimated $1.9M sold.

SG3 Management first reported a position in AGL in Q1 2022 and held it in 1 quarter. The position peaked at $1.9M in Q1 2022. 148 funds tracked by Wall St. Rank hold AGL as of Q2 2022.

SG3 Management reported no remaining Agilon Health position as of Q2 2022 after selling out during the quarter.
SG3 Management sold 3,000 Agilon Health shares in Q2 2022, an estimated $1.9M.
SG3 Management first reported a position in Agilon Health in Q1 2022 and held it in 1 quarter.
SG3 Management's Agilon Health position peaked at $1.9M in Q1 2022.
148 funds tracked by Wall St. Rank held Agilon Health as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.